At Capsida, the scale at which we have engineered capsids is unrivaled. Using our fully industrialized and roboticized screening method, our scientists assess large, diverse engineered capsid libraries for CNS and the eye in non-human primates to quickly identify optimal capsids for disease targets. To quickly advance our mission of providing meaningful therapeutic opportunities for patients with unmet medical need, Capsida characterizes the novel mechanisms of action that enable our engineered capsids to cross biological barriers, optimizes cargo and evolves preclinical disease proof-of-concept in parallel with capsid engineering. Our engineered capsids can be optimized to deliver a broad range of cargo modalities.

We have built state-of-the-art cGMP manufacturing capabilities to perform everything in-house. We streamline the entire process, from selecting our therapies for manufacturability through scalable process development. Ultimately, this helps us get therapeutics to patients sooner.